Last reviewed · How we verify
NCT05270720
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
Phase 1 trial testing dendritic cell in Recurrent Ovarian Cancer in 9 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | West China Second University Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 1 September 2022 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- dendritic cell — full drug profile →
Conditions studied
- Recurrent Ovarian Cancer — all drugs for Recurrent Ovarian Cancer →
Sponsor
West China Second University Hospital
Who can join
Adults 18 to 75, female only, with Recurrent Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effective treatments are desperately needed for ovarian cancer patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to ovarian cancer patients. Secondary outcomes will be evaluated such as patient pharmacodynamics， progression-free survival and overall survival.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x -
Dendritic cell subsets and implications for cancer immunotherapy.
Chen MY, Zhang F, Goedegebuure SP, Gillanders WE. · · 2024 · cited 24× · PMID 38903502 · DOI 10.3389/fimmu.2024.1393451 -
Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer.
Caro AA, Deschoemaeker S, Allonsius L, Coosemans A, et al · · 2022 · cited 22× · PMID 36011029 · DOI 10.3390/cancers14164037 -
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876 -
Limitations and potential of immunotherapy in ovarian cancer.
Kumar S, Acharya S, Karthikeyan M, Biswas P, et al · · 2023 · cited 11× · PMID 38264664 · DOI 10.3389/fimmu.2023.1292166 -
Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer.
Gildiz S, Minko T. · · 2023 · cited 5× · PMID 36376606 · DOI 10.1007/s11095-022-03434-4 -
Research and Clinical Progress of Therapeutic Tumor Vaccines.
Dong C, Li Z, Tan D, Sun H, et al · · 2025 · cited 3× · PMID 40733649 · DOI 10.3390/vaccines13070672 -
Development of a personalized dendritic cell vaccine and single-cell RNA sequencing-guided assessment of its cell type composition.
Li Q, Yang C, Tian H, Jiang J, et al · · 2023 · cited 3× · PMID 36443171 · DOI 10.1016/j.jcyt.2022.10.013
Verify or expand the search:
- PubMed search for NCT05270720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Ovarian Cancer
Currently open trials in the same condition.
- NCT06769425 — HS-10502 Combination Treatment in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07495384 — Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Pro · NA · recruiting
- NCT06560112 — An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer · Phase 2 · recruiting
- NCT05610735 — Combination Therapy for Recurrent Ovarian Cancer · Phase 1, PHASE2 · recruiting
- NCT06107868 — Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer · Phase 1 · active not recruiting
Other West China Second University Hospital trials
Trials by the same sponsor.
- NCT07371182 — Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions · NA · recruiting
- NCT07511920 — A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese Children · not yet recruiting
- NCT07508072 — Comparison of High-Definition Electronic Magnifying Endoscopy With Image-Enhanced Technology Versus Colposcopy in the De · NA · not yet recruiting
- NCT07431060 — Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis · NA · recruiting
- NCT07201259 — Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Follo · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05270720 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Second University Hospital
- Last refreshed: 8 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing